We've found
184,457
clinical trials
We've found
184,457
clinical trials
Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Cardiology / Vascular Diseases Clinical Trial
Updated: 12/31/1969
Renal Nerve Denervation in Patients With Hypertension and Paroxysmal and Persistent Atrial Fibrillation
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Cardiology / Vascular Diseases Clinical Trial
Updated: 12/31/1969
Renal Nerve Denervation in Patients With Hypertension and Paroxysmal and Persistent Atrial Fibrillation
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Carotid Stenosis Clinical Trial
Updated: 12/31/1969
Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials

Chronic Kidney Disease, Secondary Hyperparathyroidism Clinical Trial
Updated: 3/30/2016
A Study to Assess the Efficacy and Safety of Cinacalcet in Pediatric Subjects With SHPT and CKD on Dialysis
Status: Enrolling,
Phase
III
Updated: 3/30/2016
Click here to add this to my saved trials

Chronic Kidney Disease, Secondary Hyperparathyroidism Clinical Trial
Updated: 3/30/2016
A Study to Assess the Efficacy and Safety of Cinacalcet in Pediatric Subjects With SHPT and CKD on Dialysis
Status: Enrolling,
Phase
III
Updated: 3/30/2016
Click here to add this to my saved trials

Chronic Kidney Disease, Secondary Hyperparathyroidism Clinical Trial
Updated: 3/30/2016
A Study to Assess the Efficacy and Safety of Cinacalcet in Pediatric Subjects With SHPT and CKD on Dialysis
Status: Enrolling,
Phase
III
Updated: 3/30/2016
Click here to add this to my saved trials

Chronic Kidney Disease, Secondary Hyperparathyroidism Clinical Trial
Updated: 3/30/2016
A Study to Assess the Efficacy and Safety of Cinacalcet in Pediatric Subjects With SHPT and CKD on Dialysis
Status: Enrolling,
Phase
III
Updated: 3/30/2016
Click here to add this to my saved trials

Chronic Kidney Disease, Secondary Hyperparathyroidism Clinical Trial
Updated: 3/30/2016
A Study to Assess the Efficacy and Safety of Cinacalcet in Pediatric Subjects With SHPT and CKD on Dialysis
Status: Enrolling,
Phase
III
Updated: 3/30/2016
Click here to add this to my saved trials

Chronic Kidney Disease, Secondary Hyperparathyroidism Clinical Trial
Updated: 3/30/2016
A Study to Assess the Efficacy and Safety of Cinacalcet in Pediatric Subjects With SHPT and CKD on Dialysis
Status: Enrolling,
Phase
III
Updated: 3/30/2016
Click here to add this to my saved trials

Differentiated Thyroid Cancer Clinical Trial
Updated: 3/15/2016
An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated: 3/15/2016
Click here to add this to my saved trials

Differentiated Thyroid Cancer Clinical Trial
Updated: 3/15/2016
An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated: 3/15/2016
Click here to add this to my saved trials

Head and Neck Squamous Cell Cancer Clinical Trial
Updated: 4/7/2016
Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)
Status: Enrolling,
Phase
III
Updated: 4/7/2016
Click here to add this to my saved trials

Head and Neck Squamous Cell Cancer Clinical Trial
Updated: 4/7/2016
Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)
Status: Enrolling,
Phase
III
Updated: 4/7/2016
Click here to add this to my saved trials

Head and Neck Squamous Cell Cancer Clinical Trial
Updated: 4/7/2016
Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)
Status: Enrolling,
Phase
III
Updated: 4/7/2016
Click here to add this to my saved trials

Head and Neck Squamous Cell Cancer Clinical Trial
Updated: 4/7/2016
Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)
Status: Enrolling,
Phase
III
Updated: 4/7/2016
Click here to add this to my saved trials

Head and Neck Squamous Cell Cancer Clinical Trial
Updated: 4/7/2016
Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)
Status: Enrolling,
Phase
III
Updated: 4/7/2016
Click here to add this to my saved trials

Head and Neck Squamous Cell Carcinoma HNSCC Clinical Trial
Updated: 9/23/2015
Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055)
Status: Enrolling,
Phase
II
Updated: 9/23/2015
Click here to add this to my saved trials

Head and Neck Squamous Cell Carcinoma HNSCC Clinical Trial
Updated: 9/23/2015
Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055)
Status: Enrolling,
Phase
II
Updated: 9/23/2015
Click here to add this to my saved trials

Head and Neck Squamous Cell Carcinoma HNSCC Clinical Trial
Updated: 9/23/2015
Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055)
Status: Enrolling,
Phase
II
Updated: 9/23/2015
Click here to add this to my saved trials

Head and Neck Squamous Cell Carcinoma HNSCC Clinical Trial
Updated: 9/23/2015
Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055)
Status: Enrolling,
Phase
II
Updated: 9/23/2015
Click here to add this to my saved trials

Head and Neck Squamous Cell Carcinoma HNSCC Clinical Trial
Updated: 9/23/2015
Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055)
Status: Enrolling,
Phase
II
Updated: 9/23/2015
Click here to add this to my saved trials

Urothelial Cancer Clinical Trial
Updated: 9/23/2015
A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)
Status: Enrolling,
Phase
III
Updated: 9/23/2015
Click here to add this to my saved trials

Urothelial Cancer Clinical Trial
Updated: 9/23/2015
A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)
Status: Enrolling,
Phase
III
Updated: 9/23/2015
Click here to add this to my saved trials

Gastroparesis Clinical Trial
Updated: 12/12/2016
The Diabetic and Idiopathic Gastroparesis Efficacy, Safety, and Tolerability (DIGEST) Study
Status: Enrolling,
Phase
II
Updated: 12/12/2016
Click here to add this to my saved trials

Gastroparesis Clinical Trial
Updated: 12/12/2016
The Diabetic and Idiopathic Gastroparesis Efficacy, Safety, and Tolerability (DIGEST) Study
Status: Enrolling,
Phase
II
Updated: 12/12/2016
Click here to add this to my saved trials

Bacterial Infection Clinical Trial
Updated: 4/12/2016
Pharmacokinetics and Safety of Solithromycin in Adolescents and Children
Status: Enrolling,
Phase
I
Updated: 4/12/2016
Click here to add this to my saved trials

Bacterial Infection Clinical Trial
Updated: 4/12/2016
Pharmacokinetics and Safety of Solithromycin in Adolescents and Children
Status: Enrolling,
Phase
I
Updated: 4/12/2016
Click here to add this to my saved trials

Bacterial Infection Clinical Trial
Updated: 4/12/2016
Pharmacokinetics and Safety of Solithromycin in Adolescents and Children
Status: Enrolling,
Phase
I
Updated: 4/12/2016
Click here to add this to my saved trials

Bacterial Infection Clinical Trial
Updated: 4/12/2016
Pharmacokinetics and Safety of Solithromycin in Adolescents and Children
Status: Enrolling,
Phase
I
Updated: 4/12/2016
Click here to add this to my saved trials

HIV-1 Clinical Trial
Updated: 10/28/2015
Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018)
Status: Enrolling,
Phase
III
Updated: 10/28/2015
Click here to add this to my saved trials

HIV-1 Clinical Trial
Updated: 10/28/2015
Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018)
Status: Enrolling,
Phase
III
Updated: 10/28/2015
Click here to add this to my saved trials

HIV-1 Clinical Trial
Updated: 10/28/2015
Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018)
Status: Enrolling,
Phase
III
Updated: 10/28/2015
Click here to add this to my saved trials

HIV-1 Clinical Trial
Updated: 10/28/2015
Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018)
Status: Enrolling,
Phase
III
Updated: 10/28/2015
Click here to add this to my saved trials

HIV-1 Clinical Trial
Updated: 10/28/2015
Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018)
Status: Enrolling,
Phase
III
Updated: 10/28/2015
Click here to add this to my saved trials

HIV-1 Clinical Trial
Updated: 10/28/2015
Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018)
Status: Enrolling,
Phase
III
Updated: 10/28/2015
Click here to add this to my saved trials

HIV-1 Clinical Trial
Updated: 10/28/2015
Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018)
Status: Enrolling,
Phase
III
Updated: 10/28/2015
Click here to add this to my saved trials

Clinical Trial
Updated: 2/7/2018
Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck
Status: Enrolling,
Phase
II
Updated: 2/7/2018
Click here to add this to my saved trials

Chronic Pain Clinical Trial
Updated: 4/25/2016
Patient Activation to Address Chronic Pain and Opioid Management in Primary Care
Status: Enrolling
Updated: 4/25/2016
Click here to add this to my saved trials

Orthopedics / Podiatry, Reproductive Clinical Trial
Updated: 12/31/1969
The Treatment of Progressive Early Onset Spinal Deformities: A Multi-Center Outcome Study
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials

ALK-positive Non-small Cell Lung Cancer Clinical Trial
Updated: 12/31/1969
A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Acute Promyelocytic Leukemia With PML-RARA Clinical Trial
Updated: 12/31/1969
Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Acute Promyelocytic Leukemia With PML-RARA Clinical Trial
Updated: 12/31/1969
Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Acute Promyelocytic Leukemia With PML-RARA Clinical Trial
Updated: 12/31/1969
Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Tricuspid Regurgitation Clinical Trial
Updated: 12/31/1969
Heterotopic Implantation Of the Edwards-Sapien Transcatheter Aortic Valve in the Inferior VEna Cava for the Treatment of Severe Tricuspid Regurgitation (HOVER)
Status: Enrolling,
Phase
IV
Updated: 12/31/1969
Click here to add this to my saved trials

Metastatic Pancreatic Cancer Clinical Trial
Updated: 12/31/1969
Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Influenza A Clinical Trial
Updated: 7/28/2015
Study of Acute Uncomplicated Seasonal Influenza A in Adult Subjects
Status: Enrolling,
Phase
II
Updated: 7/28/2015
Click here to add this to my saved trials
